China approves first domestic nine-valent HPV vaccine

China's first domestically produced nine-valent HPV vaccine has been approved for market, breaking a decade-long foreign monopoly on the technology. This vaccine will help prevent cervical, genital, and other cancers. Developed by a team from Xiamen University and Wantai Biological, the vaccine is the second of its kind globally. It offers protection against nine strains of the human papillomavirus, and clinical trials show it is highly effective. The vaccine's approval follows the successful development of a domestically produced bivalent HPV vaccine. The new vaccine is also approved for use in men, and is a significant step in preventing HPV-related diseases.